Jove
Visualize
Contact Us

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efgartigimod efficacy and safety in refractory myasthenia gravis: UK's first real-world experience.

Journal of neurology, neurosurgery, and psychiatry·2025
Same author

Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis.

The Cochrane database of systematic reviews·2022
Same author

Patent foramen ovale and migraine: what is the relationship between the two?

Journal of cardiology·2013
Same author

Current and emerging treatments for the management of myasthenia gravis.

Therapeutics and clinical risk management·2011
Same author

Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis.

The Cochrane database of systematic reviews·2011
Same author

Managing patients with amyotrophic lateral sclerosis.

European journal of internal medicine·2009
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Statin induced myotoxicity.

Sivakumar Sathasivam1

  • 1The Walton Centre NHS Foundation Trust, Lower Lane, Liverpool L9 7LJ, United Kingdom. s_sathasivam@hotmail.com

European Journal of Internal Medicine
|May 8, 2012
PubMed
Summary
This summary is machine-generated.

Statins effectively prevent cardiovascular diseases but can cause muscle damage (myotoxicity). Early diagnosis and management, including immunosuppression for autoimmune myopathy, are crucial for patient safety.

Related Experiment Videos

Area of Science:

  • Cardiology
  • Neurology
  • Pharmacology

Background:

  • Statins are widely used for cardiovascular disease prevention.
  • Statin-induced myotoxicity is a common adverse effect, ranging from mild muscle pain to severe rhabdomyolysis.
  • Necrotizing autoimmune myopathy is a potential long-term consequence of statin use.

Purpose of the Study:

  • To review the pathophysiology, risk factors, diagnosis, and management of statin-induced myotoxicity.
  • To highlight the spectrum of muscle-related adverse events associated with statin therapy.
  • To emphasize the importance of recognizing and managing statin-induced myotoxicity, including autoimmune forms.

Main Methods:

  • Review of existing literature on statin-induced myotoxicity.
  • Clinical case analysis of patients experiencing muscle symptoms during statin therapy.
  • Discussion of diagnostic tools including creatine kinase levels, electromyography, and muscle biopsy.
  • Evaluation of management strategies, including statin cessation, alternative lipid-lowering agents, and immunosuppression for autoimmune myopathy.

Main Results:

  • Statin-induced myotoxicity presents a spectrum of symptoms, from asymptomatic creatine kinase elevation to severe myositis and rhabdomyolysis.
  • Persistent muscle symptoms after statin cessation may indicate necrotizing autoimmune myopathy.
  • Accurate diagnosis relies on clinical evaluation and specific investigations.
  • Management requires a tailored approach based on the severity and type of myotoxicity.

Conclusions:

  • Statin-induced myotoxicity is a significant clinical challenge requiring vigilant monitoring.
  • Early and accurate diagnosis is essential for effective management.
  • Immunosuppressive therapy is indicated for necrotizing autoimmune myopathy secondary to statin use.
  • Understanding the risks and management strategies is key to optimizing cardiovascular risk reduction with statins.